<DOC>
	<DOCNO>NCT00501020</DOCNO>
	<brief_summary>This randomize , double-blind , double dummy , multicenter study ass safety , efficacy tolerability addition RSG ( rosiglitazone ) sub-maximal MET ( metformin ) combination relative maximal MET monotherapy subject type 2 DM ( diabetes mellitus ) . The total duration study approximately 20 month . The study consist two-week washout period , four seven-week MET titration period , 24-week randomize treatment phase subject , stratify prior therapy , receive either RSG + MET combination therapy MET monotherapy .</brief_summary>
	<brief_title>Comparison Efficacy Tolerability Addition AVANDIA Submaximal Doses Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Subjects diagnosis Type 2 DM define criterion American Diabetes Association . Exceptions grant subject age 75 casebycase basis express permission study sponsor . Females postmenopausal ( i.e. , &gt; 6 month without menstrual period ) , surgically sterile , use acceptable contraceptive measure ( oral contraceptive , Norplant , DepoProvera , IUD , diaphragm spermicide condom ) . Subjects previously treat either diet exercise oral therapy . Any subject receive MET MET plus Sulfonylurea ( SU ) must receive MET 1000mg/day least three month prior study entry . Subjects must stop previous treatment thiazolidinediones ( TZDs ) least three month prior screen . Subjects Body Mass Index ( BMI ) &gt; =27 kg/m2 . Subjects sign Informed Consent . Subjects received monotherapy treatment within last three month prior study entry drugnaives HbA1c level 7 % 10 % , inclusive . Subjects receive prior combination treatment HbA1c least 6.5 % 8.5 % , inclusive . Subjects FPG &lt; 270 mg/dL screen visit 2 , must FPG &gt; =126 mg/dL either screen MET titration period ( visit 2 , runin ) entry treatment phase study . Females lactate , pregnant , plan become pregnant . Any clinically significant abnormality identify chest Xray , screen physical examination , laboratory test , electrocardiogram , , judgment investigator , would preclude safe completion study . Use TZDs investigational drug glycemic control within three month prior study entry irregardless treatment regimen , use investigational agent ( related glycemic management ) within 30 day five halflives ( whichever longer ) precede study entry . Subjects FPG &gt; =270 mg/dL screen . Subjects prior history hepatocellular reaction severe edema associate troglitazone current TZD . History significant hypersensitivity TZDs , biguanides , compound similar chemical structure . Subjects currently use insulin discontinue use glycemic control within last three month prior study entry . History acute chronic metabolic acidosis . Presence clinically significant renal hepatic disease ( i.e. , male subject serum creatinine &gt; 1.5 mg/dL ; female subject serum creatinine &gt; 1.4 mg/dL ; ALT , AST , total bilirubin , GGT , alkaline phosphatase &gt; 2.5 time upper limit reference range ) . Anemia define hemoglobin concentration &lt; 11.0 g/dL male &lt; 10.0 g/dL female . Presence unstable severe angina coronary insufficiency , congestive heart failure require pharmacologic treatment . Systolic BP &gt; 170mmHg diastolic BP &gt; 100mmHg antihypertensive treatment . Recent history suspicion current drug abuse alcohol abuse ( define consumption 35 unit alcohol per week . Noncompliance study medication MET titration period ( runin ) . Subjects , receive anticipated receive radiocontrast dye MET titration ( runin ) randomize treatment period study . Subjects unwilling unable comply procedure describe protocol . Subjects unable read understand English language exclude study due administration QOL assessment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>metformin</keyword>
	<keyword>rosiglitazone</keyword>
</DOC>